Re-assessment of the Actual Benefit and Improvement in Actual Benefit for the symptomatic treatment of idiopathic restless legs syndrome (RLS at the request of the Committee (pursuant to article R 163-21 of the French Social Security Code).
-
Clinical Benefit
Moderate
Moderate in patients with very severe idiopathic RLS.
Clinical Added Value
minor
SIFROL provides a minor improvement in actual benefit (IAB IV) in the management of patients with very severe idiopathic restless legs syndrome.
Listen
